BioSpace News Archive

Centene Corporation announced its subsidiary WellCare of Kentucky has been selected by the state of Kentucky to continue serving the commonwealth’s Medicaid managed care program statewide.

SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske , D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled mu

New BRILINTA indication expands treatment to high-risk coronary patients without a history of stroke or heart attack

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 8:00 AM ET. A live webcast of the Company’s presentation will available by visiting http://wsw.com/webcast/jeff126/enlv/ . ABOUT ENLIVEX Enlivex is a clinical stage immunotherapy company, developing an allogenei

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Erin Lavelle to the company’s Board of Directors.

Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the fourth quarter (“4Q20”) and full year ended March 31, 2020 (“FY20”).

NOVA Thin Film Pharmaceuticals LLC announced its formation and the commencement of its soluble thin film operations.

Pharmacology and preclinical efficacy reported in rodent models of cognition and behavior Detailed insight into mechanism of action

NDA is supported by positive data from two Phase 3 studies and a long-term extension study, demonstrating sustained reduction in heavy menstrual bleeding while maintaining bone health through one year If approved, relugolix combination tablet would be the first once-daily, oral treatment for women with heavy menstrual bleeding associated with uterine fibroids in the U.S. BASEL, Switzerland, June 01, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on